Becton, Dickinson and Company - BDX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $281.40
  • Forecasted Upside: 22.99%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$228.79
▼ -1.56 (-0.68%)

This chart shows the closing price for BDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Becton, Dickinson and Company Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDX

Analyst Price Target is $281.40
▲ +22.99% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Becton, Dickinson and Company in the last 3 months. The average price target is $281.40, with a high forecast of $312.00 and a low forecast of $260.00. The average price target represents a 22.99% upside from the last price of $228.79.

This chart shows the closing price for BDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Becton, Dickinson and Company. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2024BarclaysBoost TargetOverweight ➝ Overweight$305.00 ➝ $312.00Low
2/5/2024BarclaysBoost TargetOverweight ➝ Overweight$301.00 ➝ $305.00Low
1/3/2024Raymond JamesBoost TargetOutperform ➝ Outperform$269.00 ➝ $275.00Low
12/4/2023Morgan StanleyLower TargetOverweight ➝ Overweight$310.00 ➝ $280.00Low
11/10/2023Piper SandlerLower TargetOverweight ➝ Overweight$305.00 ➝ $280.00Low
11/10/2023Raymond JamesLower TargetOutperform ➝ Outperform$304.00 ➝ $269.00Low
10/2/2023CitigroupLower Target$282.00 ➝ $260.00Low
8/21/2023CitigroupBoost TargetNeutral ➝ Neutral$260.00 ➝ $282.00Low
8/7/2023BarclaysBoost TargetOverweight ➝ Overweight$284.00 ➝ $303.00Low
8/4/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$295.00 ➝ $310.00Low
8/4/2023Raymond JamesLower TargetOutperform ➝ Outperform$305.00 ➝ $304.00Low
7/24/2023Piper SandlerBoost TargetOverweight$290.00 ➝ $305.00Low
7/24/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$305.00Low
5/8/2023BarclaysBoost Target$282.00 ➝ $284.00Low
5/5/2023Piper SandlerUpgradeNeutral ➝ Overweight$260.00 ➝ $290.00Low
4/4/2023Evercore ISILower TargetOutperform$280.00 ➝ $275.00Low
2/3/2023Morgan StanleyBoost TargetOverweight$290.00 ➝ $295.00Low
2/2/2023Piper SandlerBoost TargetNeutral$245.00 ➝ $260.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$275.00 ➝ $290.00Low
1/3/2023Bank of AmericaUpgradeNeutral ➝ Buy$250.00 ➝ $290.00Low
12/12/2022CitigroupUpgradeSell ➝ Neutral$221.00 ➝ $250.00Low
11/23/2022The Goldman Sachs GroupLower TargetBuy$319.00 ➝ $272.00Low
11/16/2022Evercore ISILower Target$270.00N/A
11/16/2022CowenLower Target$255.00N/A
11/14/2022CitigroupLower Target$227.00 ➝ $220.00Low
11/11/2022William BlairReiterated RatingOutperformLow
11/10/2022Piper SandlerLower TargetNeutral$255.00 ➝ $245.00Low
10/11/2022Morgan StanleyBoost TargetOverweight$272.00 ➝ $275.00Low
10/5/2022CitigroupLower Target$235.00 ➝ $227.00Low
8/16/2022The Goldman Sachs GroupBoost TargetBuy$278.00 ➝ $319.00Low
7/18/2022Stifel NicolausLower Target$290.00 ➝ $280.00Low
7/15/2022Morgan StanleyLower TargetOverweight$282.00 ➝ $272.00Low
7/11/2022CitigroupDowngradeNeutral ➝ Sell$265.00 ➝ $235.00N/A
6/24/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$275.00Low
5/5/2022Piper SandlerLower Target$265.00 ➝ $255.00Low
4/11/2022Morgan StanleyBoost TargetOverweight$293.00 ➝ $295.00Medium
4/1/2022Wells Fargo & CompanyBoost TargetEqual Weight$275.00 ➝ $285.00High
3/28/2022Morgan StanleyLower TargetOverweight$310.00 ➝ $293.00Low
3/1/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
2/28/2022ArgusBoost Target$275.00 ➝ $310.00Low
2/4/2022Morgan StanleyBoost TargetOverweight$300.00 ➝ $310.00Low
2/4/2022SVB LeerinkBoost TargetMarket Perform$270.00 ➝ $275.00Low
1/7/2022Morgan StanleyBoost TargetOverweight$285.00 ➝ $300.00High
12/8/2021Piper SandlerDowngradeOverweight ➝ Neutral$285.00 ➝ $260.00Medium
10/22/2021SVB LeerinkReiterated RatingMarket PerformLow
8/6/2021SVB LeerinkLower TargetMarket Perform$260.00 ➝ $250.00Medium
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$276.93 ➝ $265.00Low
7/20/2021SVB LeerinkReiterated RatingMarket PerformLow
5/24/2021BarclaysInitiated CoverageEqual Weight$270.00Medium
5/7/2021SVB LeerinkLower TargetMarket Perform$270.00 ➝ $260.00High
2/5/2021CitigroupBoost TargetNeutral$273.00 ➝ $280.00Low
2/4/2021Piper SandlerBoost TargetPositive ➝ Overweight$275.00 ➝ $280.00Low
1/29/2021Raymond JamesBoost TargetOutperform$270.00 ➝ $282.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$265.00Medium
12/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$262.00 ➝ $297.00Medium
11/6/2020Morgan StanleyLower TargetEqual Weight$270.00 ➝ $262.00Low
10/12/2020Raymond JamesLower TargetOutperform$285.00 ➝ $270.00Low
10/2/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyMedium
8/27/2020Morgan StanleyLower TargetEqual Weight$285.00 ➝ $270.00High
8/10/2020UBS GroupBoost TargetNeutral$265.00 ➝ $280.00Low
8/10/2020Morgan StanleyBoost TargetEqual Weight$248.00 ➝ $285.00Low
8/7/2020Raymond JamesBoost TargetOutperform$265.00 ➝ $285.00Medium
7/15/2020SVB LeerinkBoost TargetMarket Perform$262.00 ➝ $277.00Medium
7/9/2020BarclaysUpgradeEqual Weight ➝ Overweight$300.00Medium
7/2/2020William BlairReiterated RatingOutperformLow
6/25/2020Morgan StanleyLower TargetEqual Weight$255.00 ➝ $248.00High
6/25/2020Raymond JamesLower TargetPositive ➝ Outperform$290.00 ➝ $265.00High
5/31/2020The Goldman Sachs GroupInitiated CoverageBuy$278.00Low
5/14/2020Piper SandlerBoost TargetOverweight$286.00 ➝ $296.00Low
5/12/2020KeyCorpReiterated RatingHoldLow
5/8/2020SVB LeerinkReiterated RatingMarket Perform$245.00 ➝ $262.00Low
5/8/2020CfraLower TargetHold$285.00 ➝ $278.00Medium
5/8/2020UBS GroupBoost TargetNeutral$260.00 ➝ $265.00Medium
5/8/2020Stifel NicolausBoost TargetBuy$265.00 ➝ $280.00Medium
5/8/2020Raymond JamesBoost TargetOutperform$283.00 ➝ $290.00Low
5/8/2020CitigroupBoost TargetNeutral$234.00 ➝ $260.00Low
5/8/2020Wells Fargo & CompanyReiterated RatingBuyLow
4/14/2020BarclaysReiterated RatingHold$266.00Low
4/8/2020SVB LeerinkLower TargetMarket Perform$269.00 ➝ $245.00High
4/8/2020Wells Fargo & CompanyLower TargetOverweight$279.00 ➝ $270.00High
4/1/2020Stifel NicolausLower TargetBuy$280.00 ➝ $265.00Medium
3/27/2020CitigroupLower TargetNeutral$260.00 ➝ $234.00Medium
3/27/2020Morgan StanleyLower TargetEqual Weight$271.00 ➝ $255.00Medium
3/4/2020CitigroupInitiated CoverageNeutral$260.00Medium
2/7/2020Morgan StanleyLower TargetHold ➝ Equal Weight$287.00 ➝ $271.00Medium
2/7/2020Wells Fargo & CompanyLower TargetOverweight$285.00 ➝ $279.00Medium
2/7/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$288.00 ➝ $283.00Medium
2/6/2020CowenDowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00High
2/6/2020Piper SandlerBoost TargetOverweight$279.00 ➝ $285.00High
2/6/2020CfraDowngradeBuy ➝ Hold$304.00 ➝ $285.00High
2/3/2020CowenReiterated RatingOutperform ➝ Outperform$255.00 ➝ $305.00High
1/22/2020KeyCorpBoost TargetOverweight$284.00 ➝ $298.00Low
1/8/2020BarclaysDowngradeOverweight ➝ Equal Weight$275.00Low
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$285.00 ➝ $300.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$261.00 ➝ $287.00Low
12/16/2019Stifel NicolausBoost TargetBuy$275.00 ➝ $295.00Low
11/13/2019KeyCorpLower TargetOverweight$262.00 ➝ $256.00Medium
9/6/2019Wells Fargo & CompanyBoost TargetOutperform$270.00 ➝ $290.00N/A
9/5/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/6/2019Piper Sandler CompaniesLower TargetOverweight$267.00 ➝ $266.00Medium
7/16/2019Morgan StanleyBoost TargetEqual Weight$250.00 ➝ $261.00Low
6/28/2019Raymond JamesBoost TargetStrong-Buy$265.00 ➝ $288.00Low
(Data available from 5/25/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 10 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/27/2023
  • 20 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/27/2023
  • 28 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
1/26/2024
  • 32 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/25/2024
  • 28 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 21 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 36 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 36 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $228.79
Low: $228.09
High: $230.71

50 Day Range

MA: $237.66
Low: $228.79
High: $247.45

52 Week Range

Now: $228.79
Low: $228.09
High: $287.32

Volume

1,373,384 shs

Average Volume

1,560,821 shs

Market Capitalization

$66.12 billion

P/E Ratio

50.39

Dividend Yield

1.65%

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Becton, Dickinson and Company?

The following Wall Street sell-side analysts have issued reports on Becton, Dickinson and Company in the last twelve months: Barclays PLC, Citigroup Inc., Morgan Stanley, Piper Sandler, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for BDX.

What is the current price target for Becton, Dickinson and Company?

5 Wall Street analysts have set twelve-month price targets for Becton, Dickinson and Company in the last year. Their average twelve-month price target is $281.40, suggesting a possible upside of 23.0%. Barclays PLC has the highest price target set, predicting BDX will reach $312.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $260.00 for Becton, Dickinson and Company in the next year.
View the latest price targets for BDX.

What is the current consensus analyst rating for Becton, Dickinson and Company?

Becton, Dickinson and Company currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BDX.

What other companies compete with Becton, Dickinson and Company?

How do I contact Becton, Dickinson and Company's investor relations team?

Becton, Dickinson and Company's physical mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier's listed phone number is (201) 847-6800 and its investor relations email address is [email protected]. The official website for Becton, Dickinson and Company is www.bd.com. Learn More about contacing Becton, Dickinson and Company investor relations.